The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC‑1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy.
Maha Hussain
Consultant or Advisory Role - ImClone Systems
Dana E. Rathkopf
No relevant relationships to disclose
Glenn Liu
Research Funding - ImClone Systems
Andrew J. Armstrong
Consultant or Advisory Role - Active Biotech; Amgen; Bristol-Myers Squibb; Dendreon; Medivation (U); Sanofi
Honoraria - Amgen; Dendreon; Johnson & Johnson; Pfizer; Sanofi
Research Funding - Active Biotech; Bristol-Myers Squibb; Dendreon; ImClone Systems; Medivation; Novartis; Pfizer; Sanofi
William Kevin Kelly
Consultant or Advisory Role - ImClone Systems
Anna C. Ferrari
No relevant relationships to disclose
John D. Hainsworth
No relevant relationships to disclose
Ling Yang
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
Jonathan D. Schwartz
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
Celestia S. Higano
Consultant or Advisory Role - ImClone Systems
Honoraria - ImClone Systems
Research Funding - ImClone Systems
Other Remuneration - ImClone Systems